You have been diagnosed with advanced or metastatic prostate cancer. It is a shock, you have cancer and your cancer has already spread outside of the prostate gland. Your doctor might have already told you that at this stage it is no longer curable, and technically it can be called terminal! That is a lot of stuff that has been just pushed on to your plate. Theoretically, this is correct, but for many of us, despite having this diagnosis, we will not die from the prostate cancer! Treatment today allows us to delay the cancer long enough that we will [...]
Today’s New York Times (8/23/16) had an article written by Austin Frakt, which should be of interest to all of us with prostate cancer. The article, “Why It’s Crucial to Choose the Right Hospital appeared on page A3. The entire article is best described by the first sentence, “There’s an exceeding simple way to get better health care: Choose a better hospital.” The article dealt specifically with hospital death statistics over the last 20 years from heart attacks, but its conclusions should be the same for any serious illness including prostate cancer. In a study performed by health economists from [...]
Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial
The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is the optimal timing to begin ADT. Researchers asked if immediate ADT improves overall survival compared with delayed therapy. They created a randomized, multi-center, phase 3, non-blinded trial; recruiting men from 29 oncology centers in Australia, New Zealand, and Canada. Eligibility included men with prostate cancer [...]
Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.
We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to evaluate tumor response, adverse effects, and survival in men with castrate resistant prostate cancer who had exhausted all other potential approved therapies, evaluated the novel radioligand therapy with Lu-PSMA-617. Fifty therapies using Lu-PSMA-617 were performed in 28 consecutive men with mCRPC. Data were retrospectively analyzed [...]